ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DTIL vs PLX // 10Y YIELD & FRED MACRO BETA

Precision BioSciences Inc. (NASDAQ) VS. Protalix BioTherapeutics Inc. (NYSE) • 15-METRIC TALLY: DTIL 1 — PLX 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DTIL VS. PLX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DTIL PLX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 48.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -13.00% -22.00 PLX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -6.48% — TIE /fcf-yield <GO>
Operating Margin -60.00% -10.40% -49.60 PLX /operating-margins <GO>
Net Profit Margin -60.00% -12.50% -47.50 PLX /net-margins <GO>
Revenue Growth (YoY) -50.10% -1.20% -48.90 PLX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 2/9 -1.00 PLX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 55.8 47.3 +8.51 DTIL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $205.4M $210.3M -$4.9M PLX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DTIL REV PLX REV DTIL GROSS % PLX GROSS % DTIL FCF PLX FCF
FY 2025 $34.3M $52.7M — 48.8% -$65.8M -$13.6M
FY 2024 $68.7M $53.4M — 54.5% -$58.4M $7.4M
FY 2023 $48.7M $65.5M — — -$84.1M -$1.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DTIL // BETA —
PLX // BETA —